Cargando…

Sinonasal mass lesions: A clinicopathological study with p63 and p16 immunohistochemical expressions

INTRODUCTION: The worldwide annual incidence of carcinomas of the sinonasal tract is 0.5 to 1.0 patients per 100,000 per year. P63 plays a role in epithelial development and is used as a marker for basal and myoepithelial cells. Expression of p16 occurs as a result of functional inactivation of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandal, Ankita P., Saha, Rama, Das, Chhanda, Sengupta, Arunabha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112076/
https://www.ncbi.nlm.nih.gov/pubmed/37082072
http://dx.doi.org/10.4103/jomfp.jomfp_120_21
_version_ 1785027564391104512
author Mandal, Ankita P.
Saha, Rama
Das, Chhanda
Sengupta, Arunabha
author_facet Mandal, Ankita P.
Saha, Rama
Das, Chhanda
Sengupta, Arunabha
author_sort Mandal, Ankita P.
collection PubMed
description INTRODUCTION: The worldwide annual incidence of carcinomas of the sinonasal tract is 0.5 to 1.0 patients per 100,000 per year. P63 plays a role in epithelial development and is used as a marker for basal and myoepithelial cells. Expression of p16 occurs as a result of functional inactivation of the retinoblastoma protein (pRb) by the human papilloma virus (HPV) E7 protein. AIMS: This study aims to study the histological spectrum of benign and malignant sinonasal mass lesions and to study the immunohistochemical expression of p63 in different type of sinonasal mass lesions. It also aims to ascertain the incidence of high-risk HPV in primary sinonasal mass lesions with p16 immunohistochemistry and delineate the histological spectrum of HPV-related sinonasal lesions. MATERIALS AND METHODS: This cross-sectional study was conducted on 80 cases from June 2018 to June 2020 at a tertiary care hospital. Clinical history including demographic parameters were collected in the study proforma. The gross findings of the specimens noted and histopathological examination by H&E staining done. Immunohistochemistry staining for p63 and p16 expression was performed on all cases. RESULTS: Most common age group affected was 41–60 years with male:female ratio of 1.67:1. Nonneoplastic lesions (38.7%) comprised majority of the cases followed by benign neoplastic lesions (31.3%) and malignant neoplastic lesions (30%). Among the malignant neoplastic lesions, p63 showed positive expression in 75% (p = 0.005) and p16 showed positive expression in 41.7% (p = 0.023). Among benign and nonneoplastic lesions, p63 showed positivity in 21.4% (p = 0.000) and p16 showed positivity in 44.6% (p = 0.040). CONCLUSION: We analyzed p63 and p16 expression in varied lineages like carcinomas, papillomas, and neuroectodermal differentiation arising from the sinonasal tract and also in relation to other clinicopathological parameters. This study revealed p63 expression was associated more with the squamous cell carcinomas and nasopharyngeal carcinomas. Sinonasal tract malignancies are also associated with HPV infections that are identifiable by p16 immunostaining and, thus, could provide new prospects in identifying any definite biological and clinical characteristics associated with HPV as well as advancement in the targeted therapies for this patient population.
format Online
Article
Text
id pubmed-10112076
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-101120762023-04-19 Sinonasal mass lesions: A clinicopathological study with p63 and p16 immunohistochemical expressions Mandal, Ankita P. Saha, Rama Das, Chhanda Sengupta, Arunabha J Oral Maxillofac Pathol Original Article INTRODUCTION: The worldwide annual incidence of carcinomas of the sinonasal tract is 0.5 to 1.0 patients per 100,000 per year. P63 plays a role in epithelial development and is used as a marker for basal and myoepithelial cells. Expression of p16 occurs as a result of functional inactivation of the retinoblastoma protein (pRb) by the human papilloma virus (HPV) E7 protein. AIMS: This study aims to study the histological spectrum of benign and malignant sinonasal mass lesions and to study the immunohistochemical expression of p63 in different type of sinonasal mass lesions. It also aims to ascertain the incidence of high-risk HPV in primary sinonasal mass lesions with p16 immunohistochemistry and delineate the histological spectrum of HPV-related sinonasal lesions. MATERIALS AND METHODS: This cross-sectional study was conducted on 80 cases from June 2018 to June 2020 at a tertiary care hospital. Clinical history including demographic parameters were collected in the study proforma. The gross findings of the specimens noted and histopathological examination by H&E staining done. Immunohistochemistry staining for p63 and p16 expression was performed on all cases. RESULTS: Most common age group affected was 41–60 years with male:female ratio of 1.67:1. Nonneoplastic lesions (38.7%) comprised majority of the cases followed by benign neoplastic lesions (31.3%) and malignant neoplastic lesions (30%). Among the malignant neoplastic lesions, p63 showed positive expression in 75% (p = 0.005) and p16 showed positive expression in 41.7% (p = 0.023). Among benign and nonneoplastic lesions, p63 showed positivity in 21.4% (p = 0.000) and p16 showed positivity in 44.6% (p = 0.040). CONCLUSION: We analyzed p63 and p16 expression in varied lineages like carcinomas, papillomas, and neuroectodermal differentiation arising from the sinonasal tract and also in relation to other clinicopathological parameters. This study revealed p63 expression was associated more with the squamous cell carcinomas and nasopharyngeal carcinomas. Sinonasal tract malignancies are also associated with HPV infections that are identifiable by p16 immunostaining and, thus, could provide new prospects in identifying any definite biological and clinical characteristics associated with HPV as well as advancement in the targeted therapies for this patient population. Wolters Kluwer - Medknow 2022 2022-12-22 /pmc/articles/PMC10112076/ /pubmed/37082072 http://dx.doi.org/10.4103/jomfp.jomfp_120_21 Text en Copyright: © 2022 Journal of Oral and Maxillofacial Pathology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Mandal, Ankita P.
Saha, Rama
Das, Chhanda
Sengupta, Arunabha
Sinonasal mass lesions: A clinicopathological study with p63 and p16 immunohistochemical expressions
title Sinonasal mass lesions: A clinicopathological study with p63 and p16 immunohistochemical expressions
title_full Sinonasal mass lesions: A clinicopathological study with p63 and p16 immunohistochemical expressions
title_fullStr Sinonasal mass lesions: A clinicopathological study with p63 and p16 immunohistochemical expressions
title_full_unstemmed Sinonasal mass lesions: A clinicopathological study with p63 and p16 immunohistochemical expressions
title_short Sinonasal mass lesions: A clinicopathological study with p63 and p16 immunohistochemical expressions
title_sort sinonasal mass lesions: a clinicopathological study with p63 and p16 immunohistochemical expressions
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112076/
https://www.ncbi.nlm.nih.gov/pubmed/37082072
http://dx.doi.org/10.4103/jomfp.jomfp_120_21
work_keys_str_mv AT mandalankitap sinonasalmasslesionsaclinicopathologicalstudywithp63andp16immunohistochemicalexpressions
AT saharama sinonasalmasslesionsaclinicopathologicalstudywithp63andp16immunohistochemicalexpressions
AT daschhanda sinonasalmasslesionsaclinicopathologicalstudywithp63andp16immunohistochemicalexpressions
AT senguptaarunabha sinonasalmasslesionsaclinicopathologicalstudywithp63andp16immunohistochemicalexpressions